Literature DB >> 3662644

Polyarthritis and angioimmunoblastic lymphadenopathy.

N J McHugh1, G J Campbell, J J Landreth, M R Laurent.   

Abstract

Angioimmunoblastic lymphadenopathy (AILD) is a lymphoproliferative disorder with well established clinical and histological features, one of the clinical manifestations being a peripheral polyarthritis. A case of AILD with a symmetrical non-erosive peripheral polyarthritis is described, including the findings in the synovial fluid and histology of the synovium. There was a marked reduction in the number of peripheral blood T lymphocytes bearing the CDT8 phenotype in both the peripheral blood and synovial fluid. The arthritis was difficult to control, requiring large doses of corticosteroids, which produced significant side effects. Levamisole 150 mg, one day each week, was effective in controlling the arthritis and returning the numbers of CDT8 lymphocytes to normal. The aetiology of AILD is unknown, though a defect in T cell regulation, in particular T cell suppression, with a secondary B cell proliferation has been postulated. The demonstration of reduced numbers of lymphocytes bearing the CDT8 phenotype in this patient supports that theory.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3662644      PMCID: PMC1002192          DOI: 10.1136/ard.46.7.555

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease.

Authors:  R J Lukes; B H Tindle
Journal:  N Engl J Med       Date:  1975-01-02       Impact factor: 91.245

2.  Angioimmunoblastic lymphadenopathy: a T-cell deficiency.

Authors:  P A Kosmidis; A R Axelrod; C Palacas; M Stahl
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

3.  Letter: Levamisole in angio-immunoblastic lymphadenopathy.

Authors:  J Bensa; J Faure; H Martin; J Sotto; R Schaerer
Journal:  Lancet       Date:  1976-05-15       Impact factor: 79.321

4.  Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course.

Authors:  G Frizzera; E M Moran; H Rappaport
Journal:  Am J Med       Date:  1975-12       Impact factor: 4.965

5.  Immunoblastic sarcoma with features of Sjögren's syndrome and systemic lupus erythematosus in a patient with immunoblastic lymphadenopathy.

Authors:  D A Pierce; R Stern; R Jaffe; J Zulman; N Talal
Journal:  Arthritis Rheum       Date:  1979-08

6.  Angio-immunoblastic lymphadenopathy: report of ten cases and review of the literature.

Authors:  M H Cullen; A G Stansfeld; R T Oliver; T A Lister; J S Malpas
Journal:  Q J Med       Date:  1979-01

7.  Arthritis and angioimmunoblastic lymphadenopathy.

Authors:  P G Davies; J N Fordham
Journal:  Ann Rheum Dis       Date:  1983-10       Impact factor: 19.103

8.  Experience and recommendations for treatment schedule of levamisole in rheumatoid arthritis.

Authors:  E M Veys; H Mielants
Journal:  J Rheumatol Suppl       Date:  1978

9.  Restoration of defective cellular immunity by levamisole in a patient with immunoblastic lymphadenopathy.

Authors:  J Ellegaard; A M Boesen
Journal:  Scand J Haematol       Date:  1976-07

10.  Angioimmunoblastic lymphadenopathy associated with polyarthritis.

Authors:  R S Rothwell; M J Mant; P Davis
Journal:  Ann Rheum Dis       Date:  1980-08       Impact factor: 19.103

View more
  3 in total

1.  Angioimmunoblastic T-Cell Lymphoma with Polyarthritis Resembling Rheumatoid Arthritis.

Authors:  Ralph Yachoui; Nouman Farooq; Jonathan V Amos; Gene R Shaw
Journal:  Clin Med Res       Date:  2016-12

2.  Polyarthritis, rash and lymphadenopathy: case reports of two patients with angioimmunoblastic lymphadenopathy presenting to a rheumatology clinic.

Authors:  M A Layton; C Musgrove; P T Dawes
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  Paraneoplastic Inflammatory Arthritis.

Authors:  Fawad Rast; Konstantinos Parperis; Surabhi Amar; Mohammed Al-Charakh
Journal:  Cureus       Date:  2018-05-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.